ClinicalTrials.gg
RecruitingNCT06747884TREAT-EXTUpdated Aug 11, 2026

Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension

An observational study in Congenital Myotonic Dystrophy, Childhood Myotonic Dystrophy and Myotonic Dystrophy, sponsored by Virginia Commonwealth University. Recruiting at 4 sites in 2 countries. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Virginia Commonwealth University · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Myotonic Dystrophy with a site in United States — 23 open to participants now, 27 under way, 4 of them phase 3. Myotonic Dystrophy · United States.

Planned enrollment
10th of 21
200 · median 125
Started
2025
with 5 others
Observational
21 of 43
15 open now
Primary completion
2030-06
later than 21 of 26 live
Registered
33rd of 43
by date
Lead sponsor
6 of 43
Virginia Commonwealth University

Among the 43 studies in Myotonic Dystrophy with a site in United States, this one is the 10th largest by planned enrollment of the 21 observational ones that give a count, is one of 6 that started in 2025, is one of 21 observational ones, reaches primary completion later than 21 of the 26 other live ones, and was the 33rd registered.

Myotonic Dystrophy

127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

23 of the 43 studies in Myotonic Dystrophy with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: 3 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Myotonic Dystrophy with a site in United States, or all of them as a file.
02

Study summary

This is a natural history study to improve the types of assessments and biological samples that will be used in clinical drug trials in both congenital myotonic dystrophy and childhood myotonic dystrophy.

Read the detailed description

Congenital Myotonic Dystrophy (CDM) is a multi-systemic, dominantly inherited disorder caused by a trinucleotide repeat expansion (CTGn) in the DMPK gene. Children with CDM present at birth with respiratory insufficiency, talipes equiovarus, feeding difficulties and hypotonia. There is a 30% mortality rate in the first year of life. As children grow, they are at risk for intellectual impairment, autistic features, gastrointestinal symptoms, and motor delay. Childhood onset myotonic dystrophy (ChDM) is similarly multisystem and is classified as onset after birth but before 10 years of age. It likely represents a less severe form of CDM.

Currently, there is an ongoing therapeutic trial in adults with DM1 using an antisense oligonucleotide to target the destruction of the CTG repeat. The ability to conduct this trial in children is directly limited by the lack of available data regarding appropriate clinical endpoints and biomarkers. Although the underlying mechanism is the same in adult DM1 and CDM, there are specific challenges to directly transferring outcome measures into the CDM population. First, our cross-sectional data demonstrates age-related improvement in several functional outcome measures, such as the 6-minute walk. Second, in the adult DM1 clinical trial, RNA splicing changes in the tibialis anterior muscle are a primary endpoint because they correlate with functional measures. However, our pilot data with described splicing changes does not clearly correlate with the adult clinical phenotype.

This study is designed to establish valid and reliable clinical outcome assessments for children with congenital and childhood myotonic dystrophy, and to develop biomarkers for the condition.

This study will enroll up to 200 children with CDM and ChDM at participating sites. No treatment will be administered as part of this study. Patients will receive standard of care as determined by their treating physician. Study visits will occur at Baseline, Month 12, and Month 24.

03

Conditions studied

  • Congenital Myotonic Dystrophy
  • Childhood Myotonic Dystrophy
  • Myotonic Dystrophy

Keywords

  • DM1
  • Childhood Myotonic Dystrophy
  • Congenital Myotonic Dystrophy
  • Myotonic Dystrophy
  • Myotonia
  • Dystrophy Myotonic
  • DMCRN
  • TREAT-EXT
  • TREAT CDM
04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will enroll up to 200 children with CDM and ChDM.

Eligibility criteria

Inclusion Criteria (Congenital Myotonic Dystrophy Group):

  • Age 5-17 years, 11 months at enrollment. Lower age limit not applicable for participants who have completed ASPIRE-DM1 protocol. Upper age limit not applicable for participants who previously participated in TREAT-01-001 (TREAT-CDM) study
  • A diagnosis of CDM, defined as: children having symptoms of myotonic dystrophy in the newborn period (\<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500).
  • Written, voluntary must be obtained before any study related procedures are conducted.

Inclusion Criteria (Childhood Myotonic Dystrophy Group):

  • Age 3-17 years, 11 months at enrollment. Upper age limit not applicable for participants who previously participated in TREAT-01-001 (TREAT-CDM) study.
  • A diagnosis of ChDM, defined as: children having cognitive deficits, muscle weakness, myotonia that developed after age 1 and prior to age 10 and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500).
  • Written, voluntary informed consent must be obtained before any study related procedures are conducted.

Exclusion Criteria:

  • Any other non-DM1 illness that would interfere with the ability to undergo safe testing or would affect the interpretation of the results, in the opinion of the site investigator
  • Significant trauma within the past month
  • Internal metal or devices (exclusion for DEXA component)
  • Use of anticoagulants, such as warfarin or a direct oral anticoagulant (e.g., dabigatran) due to the increased risk of bleeding with
  • count \<50,000
  • History of a bleeding disorder
  • Participation in a clinical trial involving an product
  • History of adverse reaction to lidocaine (if participating in muscle biopsy)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Congenital myotonic dystrophy (CDM)

    Children with congenital myotonic dystrophy. No intervention will be administered to either group.

  • Childhood Myotonic Dystrophy

    Children with childhood myotonic dystrophy. No intervention will be administered to either group.

06

What researchers measure

Primary outcomes

  1. Change in ambulation over 24 months as measured by the 10-Meter Walk/Run Test (10M WRT)

    The participant will be timed walking or running along a 10-meter course. It is scored by recording the total time taken to ambulate 6 meters (m) is recorded to the nearest hundredth of a second. 6 m is then divided by the total time (in seconds) taken to ambulate and recorded in m/s.

    Time frame: Baseline, Month 12 and Month 24 visits

  2. Change in mobility (100-meter timed test)

    Mobility will be measured using the 100 Meter Timed Test (100m) in which the participant is asked to complete 2 laps around 2 cones set 25 meters apart as quickly as safely possible, running if able. The total time in seconds is recorded from when the participant starts walking until they break the plane of the 100 meter mark (i.e., when any part of the body passes the 100 meter mark).

    Time frame: Baseline, Month 12 and Month 24 visits

  3. Change in Time to Stand (SUPINE TO STAND test)

    Participant will be timed transitioning from a supine position to standing. The participant will complete one trial of this test. The test measures the participant's ability to quickly rise from a supine position on the floor with arms at their sides, to full upright posture with arms at their sides. This should be performed without external support from another person, a device, or furniture. Results will be reported in seconds.

    Time frame: Baseline, Month 12 and Month 24 visits

  4. Change in Gross Motor Function (GMFM-88)

    The Gross Motor Function Measure (GMFM-88) is an assessment tool originally designed and evaluated to measure changes in gross motor function over time or with intervention in children with cerebral palsy. The GMFM assesses functional abilities including; lying/rolling, sitting, crawling/kneeling, standing, and walking/running/jumping. A four-point ordinal scale of measurement is used to assess each item, higher scores denote better performance. A score of 4 on an item indicates a consistently normal response, a score \> 4 indicates persistent hypertonus, and a score \< 4 indicates various degrees of hypotonus.

    Time frame: Baseline, Month 12 and Month 24 visits

  5. Change in Handheld Dynamometry and Grip HAND-HELD DYNAMOMETRY (HHD)

    Maximum hand and grip strength will be assessed using a myometer. The participant will be asked to squeeze a handheld tool. When performing a hand-held dynamometry (HHD) test, you generally want a high score as it indicates greater muscle strength in the tested area; a higher number signifies a stronger muscle contraction.

    Time frame: Baseline, Month 12 and Month 24 visits

  6. 9-HOLE PEGBOARD TEST (9HPT)

    The Nine-Hole Peg Test (9-HPT) is a standardized, quantitative assessment used to measure finger dexterity. Test is measured in seconds.

    Time frame: Baseline, Month 12 and Month 24 visits

  7. VIDEO HAND OPENING TIME (vHOT)

    . The participant will squeeze the hand for three seconds then open the hand as quickly as possible. A video recording of the procedure will be obtained showing the forearm and hand but not the face. Recordings will later be assessed by a blinded reviewer to determine the hand opening time. The time is recorded in seconds.

    Time frame: Baseline, Month 12 and Month 24 visits

  8. IOWA PERFORMANCE INSTRUMENT (IOPI)

    The IOPI consists of a pressure bulb attached to a manometer. The pressure bulb will be placed on the participant's tongue. Participants are asked to push the bulb against the hard palate on the alveolar ridge just behind the upper central incisors for 3-5 seconds. This test should be repeated 3 times with a 30-second interval between trials. The maximum pressure is recorded.

    Time frame: Baseline, Month 12 and Month 24 visits

  9. CLINICAL EVALUATION OF LANGUAGE FUNDAMENTALS, 5th edition (CELF-5)

    The mean score is 100, with a standard deviation of 15, meaning that standard scores between 85-115 are within the normal range. You can calculate the level of severity for delayed skills according to how many deviations below the mean a client's score is: Mild: 70-85, Moderate 55-70 , Severe: 55 and lower.

    Time frame: Baseline, Month 12 and Month 24 visits

  10. TIMED WATER SWALLOW TEST (TWST)

    Participants will be given 3 ounces (90 mL) of water to drink from a clear cup. Safety of completing this test will be determined by the site PI with input from the parents/caregivers. Participants will be asked to drink the water as they normally would, without interruption. Straws may be used, if that is preferred. Participants will be asked to say aloud "I'm done" when they feel they've completed the task with a written cue provided as a reminder.26,27 Testing will be recorded for later quantification of time needed for test, volume ingested, volume/swallow, time/swallow, and swallow capacity (mL/swallow).

    Time frame: Baseline, Month 12 and Month 24 visits

  11. DOMAIN DELTA QUESTIONNAIRE

    A "domain delta questionnaire" is a patient-reported questionnaire used in clinical research to assess how much a patient perceives their health status has changed across specific domains (like mobility, overall health, or upper limb function) between two points in time, essentially asking them if they feel they have gotten better, worse, or stayed the same in each area compared to a baseline measurement; it's a way to measure perceived change in health related quality of life over time.

    Time frame: Baseline, Month 12 and Month 24 visits

  12. INTELLIGIBILITY IN CONTEXT SCALE (ICS)

    The ICS is a brief, 7-question, caregiver proxy instrument that rates relative intelligibility of a child with a variety of familiar and unfamiliar communication partners. It uses a 5-point Likert scale to rate the approximate level of intelligibility. ICS scores indicate a child's level of functional intelligibility, ranging from a score of 1.00 (low intelligibility) to a score of 5.00 (high intelligibility). If a child achieves an average score of 3.5, then it may be appropriate to indicate that the child is usually to sometimes understood.

    Time frame: Baseline, Month 12 and Month 24 visits

  13. PEDIATRIC QUALITY OF LIFE (PEDS QL) - GENERIC CORE SCALES

    The PedsQL evaluates a child's health-related quality of life (HRQoL) with respect to social, emotional, physical, and school functioning. he PedsQL 4.0 Generic Core Scales consist of four scales measuring HRQoL in four domains: Physical, Emotional, Social, and School functioning. Scores of 81 or higher on the PedsQL™ SCD pain scales should be considered good HRQL functioning. These children likely have had less pain that was less severe than children with lower scores and/or are managing their symptoms well.

    Time frame: Baseline, Month 12 and Month 24 visits

  14. PEDIATRIC DAYTIME SLEEPINESS SCALE (PDSS)

    SS is an 8-item scale that assesses daytime sleepiness in children as a PRO that has been used in sleep disordered breathing and epilepsy studies. 5 points Likert scale (0-4) for 8 questions concerning to sleepiness. Higher scores on PDSS were associated with reduced total sleep time, poorer school achievement, poorer anger control, and frequent illness.

    Time frame: Baseline, Month 12 and Month 24 visits

  15. BEHAVIOR RATING INVENTORY OF EXECUTIVE FUNCTION -2 (BRIEF2)

    The BRIEF2 gives you the information you need to help children and adolescents with executive dysfunction. It digs deeper than similar measures and pinpoints exactly where and why children struggle, so therapists and schools can make informed and impactful intervention and accommodation recommendations. For all BRIEF2 clinical scales and indexes, T scores from 60 to 64 are considered mildly elevated, and T scores from 65 to 69 are considered potentially clinically elevated. T scores at or above 70 are considered clinically elevated.

    Time frame: Baseline, Month 12 and Month 24 visits

  16. VINELAND ADAPTIVE BEHAVIOR SCALES THIRD EDITION (VINELAND-3)

    Vineland Adaptive Behavior Scales 3rd Edition is a leading instrument for diagnosing intellectual and developmental disabilities, providing valuable information for educational and treatment plans. Higher Internalizing and Externalizing v-scale scores indicate more problem behavior. If qualitative descriptors are desired, scores of 1 to 17 may be considered Average, 18 to 20 Elevated, and 21 to 24 Clinically Significant.

    Time frame: Baseline, Month 12 and Month 24 visits

  17. WECHSLER INTELLIGENCE SCALE FOR CHILDREN (WISC-V)

    Wechsler Intelligence Scale for Children (WISC-V) is an intelligence test that measures a child's intellectual ability and 5 cognitive domains that impact performance. Low Average: 80-89. Students who test in this range may struggle to keep up in school, but are not generally eligible for special education or assistance. Average: 90-109. Students who test in this range are average and may or may not struggle to keep up in school.

    Time frame: Baseline, Month 12 and Month 24 visits

  18. AUTISM SPECTRUM SCREENING QUESTIONNAIRE (ASSQ)

    Results consist of a total score between 0 and 54, where higher scores indicate that many characteristics of ASD were reported. A score of 13 and above indicates ASD is probable, with a true positive rate of 90% and a false positive rate of 22%.

    Time frame: Baseline, Month 12 and Month 24 visits

  19. REPETITIVE BEHAVIOR SCALE - REVISED (RBS-R)

    The RBS-R is a questionnaire that focuses exclusively on RRBs. It includes 43 items rated on a four-point Likert scale: 0=behavior does not occur; 1=behavior occurs and is a mild problem; 2=behavior occurs and is a moderate problem; and 3=behavior occurs and is a severe problem.

    Time frame: Baseline, Month 12 and Month 24 visits

07

Study locations

1 of 4 sites recruiting
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
    Not yet recruiting
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
    Not yet recruiting
    • Cassidy Nelson · Contactcnelson15@kumc.edu · 913-588-3653
    • Jeffrey Statland, MD · Principal investigator
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
    Recruiting
  • Hospital das Clínicas, University of São Paulo School of Medicine (HCFMUSP)
    Cerqueira César, São Paulo 05403-010, Brazil
    Not yet recruiting
    • Clara Gontijo Camelo, MD, PhD · Contactclaragc@gmail.com · 55 11 2661-8833
    • Clara Gontijo Camelo, MD, PhD · Principal investigator
08

References and documents

Publications

  • Bodfish JW, Symons FJ, Parker DE, Lewis MH. Varieties of repetitive behavior in autism: comparisons to mental retardation. J Autism Dev Disord. 2000 Jun;30(3):237-43. doi: 10.1023/a:1005596502855. PubMed 11055459 ↗
  • Ehlers S, Gillberg C, Wing L. A screening questionnaire for Asperger syndrome and other high-functioning autism spectrum disorders in school age children. J Autism Dev Disord. 1999 Apr;29(2):129-41. doi: 10.1023/a:1023040610384. PubMed 10382133 ↗
  • Huckabee ML, McIntosh T, Fuller L, Curry M, Thomas P, Walshe M, McCague E, Battel I, Nogueira D, Frank U, van den Engel-Hoek L, Sella-Weiss O. The Test of Masticating and Swallowing Solids (TOMASS): reliability, validity and international normative data. Int J Lang Commun Disord. 2018 Jan;53(1):144-156. doi: 10.1111/1460-6984.12332. Epub 2017 Jul 5. PubMed 28677236 ↗
  • Porter K, Smart S, Hennessey N, Cocks N. Chewing skills in two and three year old children: Gender and age comparisons on an adapted version of the test of mastication and swallowing (TOMASS-C). Int J Speech Lang Pathol. 2024 Feb;26(1):38-44. doi: 10.1080/17549507.2022.2152867. Epub 2022 Dec 13. PubMed 36511843 ↗
  • Frank U, van den Engel-Hoek L, Nogueira D, Schindler A, Adams S, Curry M, Huckabee ML. International standardisation of the test of masticating and swallowing solids in children. J Oral Rehabil. 2019 Feb;46(2):161-169. doi: 10.1111/joor.12728. Epub 2018 Oct 27. PubMed 30307651 ↗
  • Patel R, Connaghan K, Franco D, Edsall E, Forgit D, Olsen L, Ramage L, Tyler E, Russell S. "The caterpillar": a novel reading passage for assessment of motor speech disorders. Am J Speech Lang Pathol. 2013 Feb;22(1):1-9. doi: 10.1044/1058-0360(2012/11-0134). Epub 2012 Jul 30. PubMed 22846881 ↗
  • Berggren KN, Hung M, Dixon MM, Bounsanga J, Crockett B, Foye MD, Gu Y, Campbell C, Butterfield RJ, Johnson NE. Orofacial strength, dysarthria, and dysphagia in congenital myotonic dystrophy. Muscle Nerve. 2018 Sep;58(3):413-417. doi: 10.1002/mus.26176. PubMed 29901230 ↗
  • Gavazzi F, Adang L, Waldman A, Jan AK, Liu G, Lorch SA, DeMauro SB, Shults J, Pierce SR, Ballance E, Kornafel T, Harrington A, Glanzman AM, Vanderver A. Reliability of the Telemedicine Application of the Gross Motor Function Measure-88 in Patients With Leukodystrophy. Pediatr Neurol. 2021 Dec;125:34-39. doi: 10.1016/j.pediatrneurol.2021.09.012. Epub 2021 Sep 24. PubMed 34624609 ↗
  • McDonald CM, Marden JR, Shieh PB, Wong BL, Lane H, Zhang A, Nguyen H, Frean M, Trifillis P, Koladicz K, Signorovitch J. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status. J Comp Eff Res. 2023 Apr;12(4):e220190. doi: 10.57264/cer-2022-0190. Epub 2023 Feb 7. PubMed 36749302 ↗
  • Eriksson BM, Ekstrom AB, Peny-Dahlstrand M. Daily activity performance in congenital and childhood forms of myotonic dystrophy type 1: a population-based study. Dev Med Child Neurol. 2020 Jun;62(6):723-728. doi: 10.1111/dmcn.14395. Epub 2019 Nov 8. PubMed 31701525 ↗
  • Johnson NE, Ekstrom AB, Campbell C, Hung M, Adams HR, Chen W, Luebbe E, Hilbert J, Moxley RT 3rd, Heatwole CR. Parent-reported multi-national study of the impact of congenital and childhood onset myotonic dystrophy. Dev Med Child Neurol. 2016 Jul;58(7):698-705. doi: 10.1111/dmcn.12948. Epub 2015 Oct 28. PubMed 26510705 ↗
  • Johnson NE, Butterfield R, Berggren K, Hung M, Chen W, DiBella D, Dixon M, Hayes H, Pucillo E, Bounsanga J, Heatwole C, Campbell C. Disease burden and functional outcomes in congenital myotonic dystrophy: A cross-sectional study. Neurology. 2016 Jul 12;87(2):160-7. doi: 10.1212/WNL.0000000000002845. Epub 2016 Jun 15. PubMed 27306634 ↗
  • Timchenko L. Correction of RNA-Binding Protein CUGBP1 and GSK3beta Signaling as Therapeutic Approach for Congenital and Adult Myotonic Dystrophy Type 1. Int J Mol Sci. 2019 Dec 21;21(1):94. doi: 10.3390/ijms21010094. PubMed 31877772 ↗
  • Charlet-B N, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell. 2002 Jul;10(1):45-53. doi: 10.1016/s1097-2765(02)00572-5. PubMed 12150906 ↗
  • Wagner SD, Struck AJ, Gupta R, Farnsworth DR, Mahady AE, Eichinger K, Thornton CA, Wang ET, Berglund JA. Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy. PLoS Genet. 2016 Sep 28;12(9):e1006316. doi: 10.1371/journal.pgen.1006316. eCollection 2016 Sep. PubMed 27681373 ↗
  • Osborne RJ, Lin X, Welle S, Sobczak K, O'Rourke JR, Swanson MS, Thornton CA. Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum Mol Genet. 2009 Apr 15;18(8):1471-81. doi: 10.1093/hmg/ddp058. Epub 2009 Feb 17. PubMed 19223393 ↗
  • Wheeler TM. Myotonic dystrophy: therapeutic strategies for the future. Neurotherapeutics. 2008 Oct;5(4):592-600. doi: 10.1016/j.nurt.2008.08.001. PubMed 19019311 ↗
  • Mankodi A, Teng-Umnuay P, Krym M, Henderson D, Swanson M, Thornton CA. Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann Neurol. 2003 Dec;54(6):760-8. doi: 10.1002/ana.10763. PubMed 14681885 ↗
  • Mankodi A, Takahashi MP, Jiang H, Beck CL, Bowers WJ, Moxley RT, Cannon SC, Thornton CA. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell. 2002 Jul;10(1):35-44. doi: 10.1016/s1097-2765(02)00563-4. PubMed 12150905 ↗
  • Campbell C, Sherlock R, Jacob P, Blayney M. Congenital myotonic dystrophy: assisted ventilation duration and outcome. Pediatrics. 2004 Apr;113(4):811-6. doi: 10.1542/peds.113.4.811. PubMed 15060232 ↗
  • Johnson NE, Luebbe E, Eastwood E, Chin N, Moxley RT 3rd, Heatwole CR. The impact of congenital and childhood myotonic dystrophy on quality of life: a qualitative study of associated symptoms. J Child Neurol. 2014 Jul;29(7):983-6. doi: 10.1177/0883073813484804. Epub 2013 Apr 22. PubMed 23611887 ↗
  • Campbell C, Levin S, Siu VM, Venance S, Jacob P. Congenital myotonic dystrophy: Canadian population-based surveillance study. J Pediatr. 2013 Jul;163(1):120-5.e1-3. doi: 10.1016/j.jpeds.2012.12.070. Epub 2013 Feb 14. PubMed 23415617 ↗
  • Johnson NE, Butterfield RJ, Mayne K, Newcomb T, Imburgia C, Dunn D, Duval B, Feldkamp ML, Weiss RB. Population-Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of Statewide Blood Screening Program. Neurology. 2021 Feb 16;96(7):e1045-e1053. doi: 10.1212/WNL.0000000000011425. Epub 2021 Jan 20. PubMed 33472919 ↗
  • Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, Neville C, Narang M, Barcelo J, O'Hoy K, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science. 1992 Mar 6;255(5049):1253-5. doi: 10.1126/science.1546325. PubMed 1546325 ↗
  • Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, Hunter K, Stanton VP, Thirion JP, Hudson T, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell. 1992 Feb 21;68(4):799-808. doi: 10.1016/0092-8674(92)90154-5. PubMed 1310900 ↗
  • Fu YH, Pizzuti A, Fenwick RG Jr, King J, Rajnarayan S, Dunne PW, Dubel J, Nasser GA, Ashizawa T, de Jong P, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science. 1992 Mar 6;255(5049):1256-8. doi: 10.1126/science.1546326. PubMed 1546326 ↗

Individual participant data

Plan to share: No — Aggregated and deidentified data will be shared with qualified investigators upon majority approval of the DMCRN investigators.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2030, 60 months after the start.

Of 36 observational studies under Myotonic Dystrophy, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35. This study's planned 60 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2024
First posted
Dec 24, 2024
StartActual
Jun 6, 2025
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2030
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06747884
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
Jun 6, 2025
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Aug 11, 2026

Study contacts

Ruby Langeslay, MPH
Contact
Ruby.Langeslay@vcuhealth.org
804-828-6318
Nicholas Johnson, MD, MSCI, FAAN
principal investigator · Virginia Commonwealth University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion